Alseres Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals

ALSE 0.00500

0.0%

Oct 18 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jorgen Jensen who wrote (966)	1/4/2007 10:41:48 AM
From: Jorgen Jensen	of 975

Other License Information The BioAxone license agreement provides for an up-front license fee of $10 million payable in 2 installments ($2.5 million of which was paid on execution and $7.5 million due on or before March 31, 2007), possible performance milestones of up to $25 million, the majority of which are due and payable only after approval and achievement of certain specified sales goals, and on- going royalties based on sales of Cethrin after approval. To fund the initial $2.5 million of the license fee, the Company utilized borrowings available to it under the promissory notes from Robert and Thomas Gipson. The Company plans to secure additional debt or equity financing to fund the $7.5 million remainder of the license fee. Conference Call Details The company will host a conference call on January 5, 2007 at 10:00am EST to discuss the license agreement with BioAxone. To access the conference call, please dial (719) 457-2621 domestic and (800) 210-9006 internationally. The code for this conference call is 1940703. A replay of the call will be available on the IR section of our website, www.bostonlifesciences.com, until Friday, January 19, 2007.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next